靶向I型干扰素通路治疗肾小球疾病:原理与治疗机遇
本文综述I型干扰素(IFN)通路在狼疮性肾炎(LN)和局灶节段性肾小球硬化(FSGS)等肾小球疾病中的作用,指出慢性I型IFN激活可致肾脏损伤,靶向该通路可能为免疫失调患者提供临床获益。
要点
- I型IFN通路持续激活与LN和FSGS的肾脏组织损伤相关。
- APOL1风险变异合并I型IFN表达升高与CKD风险增加相关。
- 靶向I型IFN信号是免疫失调相关肾脏病的潜在治疗策略。
核心结论
- 靶向I型IFN通路可能为免疫失调相关肾小球疾病患者提供临床获益。
研究设计与样本
- 本文为叙述性综述,未报告系统检索策略或样本量。
主要发现
- I型IFN通路持续激活与LN和FSGS的肾脏组织损伤相关。
- APOL1风险变异合并I型IFN表达升高与LN和塌陷型FSGS患者CKD风险增加相关。
- I型IFN通路长期激活可导致慢性炎症、肾脏组织损伤、细胞死亡和器官功能下降。
临床怎么用
- 对免疫失调相关肾小球疾病患者,可考虑评估I型IFN通路作为治疗靶点。
局限性
- 本文为综述,未提供原始研究数据或定量分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type I interferons (IFNs) are immunostimulatory molecules that can activate the innate and adaptive immune systems. In cases of immune dysfunction, prolonged activation of the type I IFN pathway has been correlated with kidney tissue damage in a wide range of kidney disorders, such as lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Genetic mutations, such as APOL1 risk variants in conjunction with elevated type I IFN expression, are also associated with higher rates of chronic kidney disease in patients with LN and collapsing FSGS. Long-term activation of the type I IFN pathway can result in chronic inflammation, leading to kidney tissue damage, cell death, and decline in organ function. Thus, therapeutic strategies targeting type I IFN could provide clinical benefits to patients with immune dysregulation who are at risk of developing impaired kidney function. Here, we present a critical review of type I IFN signaling, the consequences of chronically elevated type I IFN expression, and therapeutic strategies targeting type I IFN signaling in the context of kidney disease.
引用
- Tumlin J, Rovin B, Anders HJ, et al. Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities. Kidney Int Rep. 2024. PMID: 39810777. doi:10.1016/j.ekir.2024.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。